AI Summary
Mesoblast announced it has met its target of at least 300 patients in the MSB-DR004 pivotal Phase 3 trial for rexlemestrocel-L in chronic low back pain due to degenerative disc disease. Top-line results are expected in mid-2027 after 12 months of follow-up, with RMAT designation potentially expediting review after a BLA filing. A potential US peak revenue above $10B with single-digit penetration underpins upside.
Sentiment Rationale
Direct trial progress and RMAT-regulatory pathway improvement strengthen odds of near-term value inflection; readout timing is a discrete event.
Trading Thesis
Long MESO on regulatory progress and potential $10B peak CLBP revenue; catalyst through 2027.
Market-Moving
- Mid-2027 top-line readout is the key catalyst for MESO.
- RMAT designation could shorten regulatory timeline and improve valuation.
- Manufacturing scale-up supports potential commercialization upon approval.
- Addressable US CLBP market exceeds 7 million; upside optionality to >$10B peak.
Key Facts
- Mesoblast hits target of ≥300 patients in MSB-DR004 pivotal CLBP trial.
- RMAT designation supports priority review; top-line results due mid-2027.
- CLBP is a large US market; potential peak revenue >$10B.
- Manufacturing scaling underway; plan to file BLA after readout.
- Primary endpoint: 12-month pain reduction; secondary QoL, function, opioid cessation.
Companies Mentioned
- Mesoblast Limited (MESO): U.S.-listed; pivotal CLBP program unafc around rexlemestrocel-L could drive 2027 catalysts.
- Mesoblast Limited (MSB): ASX listing; cross-listing mirrors MESO program progress and potential cross-market moves.
Corporate Developments
Category fits Corporate Developments; provides a strategic update on a pivotal trial, regulatory designation, and commercialization readiness that can drive MESO equity sensitivity.